Clinical trials
Interstitial Lung Disease clinical trials
Below are recruiting interstitial lung disease clinical trials, each written for real people, not researchers. We’re tracking 193 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05947422Recruiting
CT scan test for lung scarring assessment
This trial tests how well a CT scan and lung function tests can measure interstitial lung disease (ILD), which is long-term scarring or inflammation in the lungs. It may help doctors use these images and tests more accurately to track ILD.
Asyut, Asyut GovernorateAges 18–90 - NCT05892614RecruitingPhase 2
Efzofitimod for early systemic sclerosis lung scarring
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
Los Angeles, CaliforniaAges 18 years+ - NCT07077486RecruitingPhase 4
Testing telitacicept vs cyclophosphamide for lupus lung disease
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
Wuhan, HubeiAges 18–80 - NCT06247397Recruiting
High-flow therapy for long-term oxygen users
This trial tests if adding high-flow oxygen therapy to your usual long-term oxygen therapy can help you breathe better. It is for people with COPD or ILD who use oxygen at home for at least 15 hours a day.
Karlskrona, Blekinge CountyAges 18 years+ - NCT07061873Enrolling by invitation
Exercise program for adults with lung disease
This study tests a physical exercise program designed for adults with diffuse interstitial lung disease. It aims to help improve your breathing and daily function through supervised exercise in a pulmonary rehabilitation setting.
Temuco, CautínAges 18 years+ - NCT06998706RecruitingPhase 1
Testing patient's own lung stem cells for ILD
This study tests whether a patient's own lung stem cells can be used to repair damaged lungs in people with interstitial lung disease. It is an early-stage trial to see if the treatment is safe and may help improve breathing.
Qionghai, HainanAges 40–75 - NCT06987266Recruiting
Study of lung and airway disease diagnosis
This study aims to improve how doctors diagnose and classify lung conditions that affect both the air sacs and airways, such as COPD and pulmonary fibrosis. By participating, you may help advance medical knowledge and better understand your own condition.
Changsha, HunanAges 40–80 - NCT06992661RecruitingPhase 1
Inhaled RJ026 study for interstitial lung disease patients
This trial tests a single inhaled dose of RJ026 in patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF) or connective tissue disease-related ILD (CTD-ILD). It helps see how the drug moves through the body and if it's safe.
Shanghai, Shanghai MunicipalityAges 40 years+ - NCT06326957Recruiting
Online program for chronic breathlessness
This trial tests an internet-based self-guided program to help adults with chronic breathlessness. It is designed for people who still feel short of breath despite treatment for conditions like COPD, lung disease, or cancer.
LondonAges 18–110 - NCT06911632Recruiting
AI-assisted check for pulmonary hypertension in interstitial lung disease
This study uses an AI tool to help doctors decide if you should be tested for pulmonary hypertension (high blood pressure in the lungs), which can be a complication of interstitial lung disease. If the tool suggests you might have it, you may get an echocardiogram (an ultrasound of the heart) and a right heart catheterization (a test to measure pressure in the heart) to find out for sure.
Birmingham, AlabamaAges 18 years+ - NCT06844331Enrolling by invitation
Ultrasound for lung disease testing
This study tests if ultrasound can help evaluate patients with fibrosing interstitial lung disease (a type of lung scarring). It aims to see if ultrasound is a useful tool for checking your condition.
Odense, Southern DenmarkAges 18 years+ - NCT06817590RecruitingPhase 1
Nucleoside therapy for telomere disorders
This trial tests a nucleoside therapy (dC/dT) for people with telomere biology disorders, which cause premature aging and problems like low blood counts, lung or liver issues. The goal is to see if the treatment can help manage these symptoms.
Boston, MassachusettsAges 1–70 - NCT06751069Recruiting
Home exercise and coaching for lung scarring
This study tests a home-based exercise and health coaching program for people with scarring in their lungs (fibrotic ILD). The goal is to see if doing rehab at home, with support from a coach, can help you feel better and breathe easier.
Scottsdale, ArizonaAges 18 years+ - NCT06714123RecruitingPhase 2
Senicapoc for worsening lung scarring
This trial tests if the drug senicapoc can help people whose lung scarring (pulmonary fibrosis) is getting worse despite standard care. It aims to slow down the decline in lung function.
Aarhus NAges 18 years+ - NCT06644144Recruiting
P4O2: A study for people with lung scarring
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
Amsterdam, North HollandAges 18–80 - NCT06626438Recruiting
Treating lung scarring by focusing on each person's problems
This study looks at how to better treat different types of lung scarring (fibrotic ILD) by focusing on each person's specific problems. It is for adults who are already being treated for a fibrotic ILD at one of two hospitals in Perth, Australia.
Perth, Western AustraliaAges 18 years+ - NCT06615492Recruiting
Lung transplant study: comparing two ECMO methods
This study compares two ways of using a heart-lung machine (ECMO) during lung transplant surgery. The goal is to see if using ECMO only when needed works as well as using it for everyone. This could help reduce risks and improve recovery.
Edmonton, AlbertaAges 18 years+ - NCT06572384RecruitingPhase 3
Belimumab for lung scarring in autoimmune disease
This study tests whether a drug called belimumab can help people with lung scarring caused by certain autoimmune diseases (like rheumatoid arthritis or lupus). If you have active lung disease despite standard therapy, this trial may be an option.
Los Angeles, CaliforniaAges 18 years+ - NCT06574581RecruitingPhase 1/Phase 2
Adipose stem cells for connective tissue disease with lung scarring
This trial tests whether stem cells from fat tissue can help people with connective tissue diseases (like lupus or scleroderma) whose lung scarring has worsened despite standard treatments. It aims to slow or stop lung damage.
TaichungAges 20–80 - NCT06549231RecruitingPhase 3
Rituximab and mycophenolate for scleroderma lung disease
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
ToursAges 18–100 - NCT06537934Recruiting
Advanced CT scan to check heart and lung health in lung disease
This study uses a special high-resolution CT scan to look at heart and lung problems in people with a type of lung disease that gets worse over time. It may help doctors understand how the heart is affected and guide better care.
MilanAges 18 years+ - NCT06388421Recruiting
PH-ILD patient registry: tracking real-world outcomes
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Birmingham, AlabamaAges 18 years+ - NCT06325696RecruitingPhase 2
H01 for adults with lung scarring (SOLIS study)
This study tests an oral medication (H01/hymecromone) to see if it can help people with progressive lung scarring (ILD). It lasts about 12 to 24 weeks and requires good lung function without needing oxygen at rest.
Research Triangle Park, North CarolinaAges 18–100 - NCT06297096RecruitingPhase 3
Testing a two-drug combo for lung scarring in scleroderma
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
Warsaw, Masovian VoivodeshipAges 18–74
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for interstitial lung disease?
- Yes. Clin2 currently lists 193 recruiting interstitial lung disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a interstitial lung disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a interstitial lung disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.